Introduction
Despite a reduction in conditioning regimen-related toxicity, non-myeloablative stem cell transplantation (NST) remains a procedure with significant mortality due to complications of graft-versus-host disease (GVHD). 1, 2 In the matched unrelated donor (URD) setting, the incidence of grade II-IV acute GVHD after T-replete NST ranges from 49 to 63% and grade III-IV acute GVHD incidence has been as high as 39%. 1, [3] [4] [5] HLA matching is one of the most important determinants of outcomes after hematopoietic stem cell transplantation. Donor-recipient disparity at HLA-A, B and DRB1, has been associated with increased risk of GVHD, graft rejection and inferior survival following myeloablative unrelated donor stem cell transplantation. [6] [7] [8] [9] [10] More recently, HLA-C has also emerged as an important transplantation antigen. A large retrospective analysis from the NMDP demonstrated that HLA-C disparity was independently associated with a higher risk of graft failure, grade III-IV acute GVHD and mortality. 11 Petersdorf et al. have also reported that disparity at HLA-C is also associated with decreased survival, especially among patients transplanted for lowrisk disease. 12 In the non-myeloablative URD transplant setting, the association between HLA mismatching and adverse clinical outcomes is less well understood. We hereby report a retrospective analysis of URD NST patients evaluating the effect of HLA-C mismatching on transplant outcome.
Patients and methods

Study population
Patients who underwent URD NST for hematologic malignancies between July 2000 and June 2004 at the Dana-Farber Cancer Institute were considered for this study. Donor HLA selection criteria for all URD NST protocols during this time period were based on 6/6 matching at HLA-A, B and DRB1. To assess whether matching at HLA-C is important in NST, we retrospectively analyzed our URD NST series and compared transplant outcomes between patients who were retrospectively found to be mismatched at HLA-C and those who were 10/10 HLA matched at HLA-A, B, C, DRB1 and DQB1. Patients who were mismatched at other loci without any HLA-C disparity were excluded as our focus was to compare HLA-C mismatch to full match. One hundred eleven patients were included in this analysis: 78 HLA 10/10 matched and 33 mismatched at one or more HLA-C antigen/allele. Eligibility criteria for nonmyeloablative transplantation included ECOG performance status 0-2, age X18 years, negative HIV test, preserved organ function and no uncontrolled infection. Patients were required to have a hematological cancer or disorder requiring allogeneic transplantation, and were not suitable candidates for ablative transplantation based on age, prior transplant or comorbid medical condition. Disease status at transplant was considered 'low risk' or 'high risk' based upon the following: low-risk individuals had AML or ALL in first complete remission, MDS of the refractory anemia or refractory anemia with ringed sideroblasts subtypes, or CML in first chronic phase. All others were considered high risk. The Human Subjects Protection Committee of the Dana-Farber Cancer Institute/Harvard Cancer Center approved all investigational protocols. Informed consent was obtained from all patients prior to transplantation.
HLA typing and matching
Mismatch was defined as any donor-recipient pair with an antigen or allele mismatch at HLA-A, B, C, DRB1, or DQB1. Class I HLA typing was performed by both serology and PCR with sequence-specific primers (SSP). HLA typing at Class II loci was performed by SSP and/or group-specific PCR followed by restriction fragment length polymorphism (RFLP) analysis.
Transplantation protocols
All patients received a non-myeloablative conditioning regimen that consisted of intravenous busulfan (0.8 mg/kg/ day Â 4 days) and fludarabine (30 mg/m 2 /day Â 4 days) on day À6 through day À3. Unmanipulated bone marrow or peripheral blood stem cells were infused on day 0. Stem cell source (BM versus PBSC) was determined by donor or physician preference. PBSC donors were mobilized with filgrastim according to standard practice of the individual donor centers. In patients receiving PBSC, target cell dose was 1.0 Â 10 7 CD34 þ cells/kg recipient weight. Filgrastim (5 mg/kg/day) was started on day þ 1 and continued until absolute neutrophil count reached 10 9 neutrophils/l for 2 days. All patients received immune suppressive therapy as GVHD prophylaxis starting on day À3. Graft-versus-host disease prophylaxis during the study period included cyclosporine/prednisone-based regimens and tacrolimus/ mini-methotrexate-based regimens. Taper of immune suppression was generally initiated around day þ 60. No preplanned donor lymphocyte infusions (DLI) were administered. Patients received standard antiviral and PCP prophylaxis with acyclovir and atovaquone or trimethoprim-sulfamethoxazole after transplantation. Levofloxacin was given as bacterial prophylaxis until neutrophil engraftment.
Assessment of engraftment and chimerism
Neutrophil engraftment was defined as 2 consecutive days in which the absolute neutrophil count (ANC) exceeded 0.5 Â 10 9 neutrophils/l. Engraftment of platelets was defined as the first day of a 7-day span in which platelet count remained over 20 Â 10 9 platelets/l without transfusion. Immunologic graft rejection was defined as progressive to loss of donor chimerism without evidence of disease relapse in the bone marrow.
Unfractionated donor chimerism was assessed from bone marrow aspirates at approximately day þ 30 and day þ 100 post transplant. Genotypes of donor and recipient were determined using DNA extracted from pre-transplant samples. Nine short tandem repeat (STR) loci were typed using the ABI Profiler Plus Kit (Applied Biosystems, Foster City, CA, USA) and the ABI 310 genetic analyzer to resolve alleles. 'Informative' alleles that were present only in the donor or recipient were used in the chimerism calculations.
In cases of gender-mismatched donor-recipient pairs where molecular chimerism analysis was not available, assessment of donor chimerism was based on fluorescent in situ hybridization (FISH) for X and Y chromosomes, or cytogenetic analysis.
Statistical methods
Descriptive statistical analysis was performed to report patient baseline and transplant characteristics. Two-sided Fisher's exact test was used for 2 Â 2 table analysis, and two-sided Wilcoxon rank-sum test was used for two-sample comparison of continuous variables. Cumulative incidence curves for acute GVHD and 100 day mortality were constructed reflecting time to acute GVHD and time to death before day 100 without developing acute GVHD as competing risks. Potential risk factors for grade III-IV acute GVHD were examined in logistic regression analysis. Cumulative incidence curves for non-relapse death and relapse with or without death were constructed reflecting time to relapse and time to non-relapse death as competing risks. The difference between cumulative incidence curves in the presence of a competing risk was tested using the Gray method. 13 The Gray test is based on comparing weighted averages of the hazards of relapse between two groups in the presence of non-relapse death as a competing risk. Time to relapse and time to non-relapse death were measured from the date of stem cell infusion. Patients who were alive without progression were censored at the time last seen alive and progression free. Overall survival (OS) and progression-free survival were calculated using the Kaplan-Meier method. Kaplan-Meier curves were compared using log-rank tests. Progression-free survival was defined as the time between stem cell infusion and relapse or death from any cause. Overall survival was defined as the time between stem cell infusion and death from any cause. Potential prognostic factors for survival and relapse-free survival were examined in the proportional hazards model. All interaction terms were examined in both logistic and proportional hazards regression model and no interaction term was found to be significant.
Results
Patient characteristics
The study population consisted of 33 patients who were mismatched at HLA-C and 78 who were 10/10 matched at HLA-A, B, C, DRB1 and DQB1. Among the HLA-Cmismatched patients, 21 were mismatched at a single HLA-C locus, three were double mismatched at both HLA-C loci and nine were mismatched at HLA-C plus another locus:
. Overall, 78% of the mismatches at HLA-C were detectable at an antigen level. Log-rank test for survival difference between antigen and allele mismatching at HLA-C was not significant. Thus, we decided not to distinguish between antigens and allele in our analysis for HLA-C-mismatched patients.
Patient characteristics for the HLA-C-matched versus 10/10-matched cohorts are shown in Table 1 . The two groups were similar with respect to recipient age, gender, donor-recipient sex mismatch and donor-recipient CMV serological status. Distribution of patients with prior autologous transplant was also similar in the two groups.
and Hodgkin's lymphoma (n ¼ 12). Twenty-five patients (76%) in the HLA-C-mismatched group and 63 (81%) in the 10/10-matched cohort were considered to have 'highrisk' disease at transplantation (P ¼ NS). Stem cell source was predominantly G-CSF mobilized PBSC in both groups, although more patients in the HLA-C-mismatched cohort received marrow grafts (21 versus 4%, P ¼ 0.007). There were more patients in the HLA-C-mismatched cohort (n ¼ 20, 61%) who received cyclosporine/prednisone-based GVHD prophylaxis, compared to the 10/10-matched cohort (n ¼ 22, 28%), P ¼ 0.002.
Overall and progression-free survival
Patients in HLA-C-mismatched cohort had significantly inferior survival compared to those who were 10/10 matched. As shown in Figure 1 , 1-year survival among the HLA-C-mismatched patients was 39%, compared to 63% in the 10/10-matched cohort. Overall survival at 2 years was only 30% in the HLA-C-mismatched patients, compared to 51% in the 10/10-matched patients (P ¼ 0.008). In Cox proportional hazards regression analysis considering a panel of pre-transplant parameters (Table 2) , HLA-C mismatch was the only independent risk factor associated with poor survival (hazard ratio 1.85, P ¼ 0.04). High-risk disease at transplant, recipient age, sex mismatch, stem cell source (BM versus PBSC), GVHD prophylaxis regimen, and prior autologous transplantation were not significant.
To assess the impact of isolated HLA-C mismatching on survival, we performed a subset analysis restricted to the 24 patients mismatched at only HLA-C (excluding patients with combined C þ other locus mismatch), compared to the 10/10-matched cohort. Patients with isolated mismatch at HLA-C had a 2 year OS of 27%, compared to 51% for 10/10 match, P ¼ 0.02. This survival difference was significant in the Cox regression model (hazard ratio 2.1, P ¼ 0.04) adjusted for disease risk at transplant, recipient age, sex mismatch, stem cell source (BM versus PBSC), GVHD prophylaxis regimen, and prior autologous transplantation. These results demonstrate that HLA-C mismatching, either alone or in combination with other mismatches, is associated with decreased survival after NST.
Because of the difference in the distribution of GVHD prophylaxis, we further analyzed survival on the two cohorts stratified by cyclosporine/prednisone-versus tacrolimus/methotrexate-based regimens. Among the 42 patients who had received cyclosporine/prednisone-based GVHD prophylaxis, OS at 1 year was 30% for HLA-C mismatch, versus 50% for 10/10 match (P ¼ 0.06). In patients receiving tacrolimus/methotrexate-based regimens, 1-year OS were 59% for HLA-C mismatch and 71% for 10/10 match (P ¼ 0.37).
There was no significant difference in progression-free survival (PFS) between HLA-C-mismatched and 10/10-matched patients. The 1-and 2-year PFS for the HLA-Cmismatched patients were 25 and 16%, compared to 37 and 29% in the 10/10-matched cohort, respectively (P ¼ 0.08). In Cox regression analysis, no risk factor was significantly associated with decreased PFS.
Engraftment and donor chimerism
Mismatching at HLA-C did not compromise engraftment. Median time to neutrophil engraftment (ANC 4500/ml) among patients who nadired was 12 days (range 8-21) in the HLA-C-mismatched group and 13 days (range 8-21) in the 10/10-matched groups (P ¼ NS). Platelet engraftment (420 000/ml) was also similar: 21 days (range 12-52) versus 20 days (range 9-72) in the C-mismatched and 10/10-matched cohorts, respectively. Median donor chimerism for HLA-C-mismatched patients was 90% at 1 month. At 3-4 months post transplant, median donor chimerism improved to 96%, with three-quarters of the patients having donor chimerism of X99%. These results are similar to those observed among 10/10-matched patients, in whom day þ 30 and þ 100 median donor chimerism was both 96%. Graft failure, defined as complete loss of donor chimerism in the absence of disease relapse, occurred in only two patients: one (3%) in the HLA-C-mismatched group who had 55% donor chimerism in his marrow at 1 month and who lost his graft by 3 months, and one (1.3%) in the 10/10-matched group who had 100% host hematopoiesis at 1 month. The former patient was transplanted for CML in second chronic phase; the latter was transplanted for previously untreated myelodysplastic syndrome.
Graft-versus-host disease
There was a higher incidence of grade II-IV acute GVHD in the HLA-C-mismatched recipients compared to the 10/10-matched recipients, 42 versus 26% (P ¼ 0.04). The cumulative incidence of grade III-IV acute GVHD was 33% for the C-mismatched cohort and 12% in the 10/10-matched group (P ¼ 0.01), when 100-day mortality was taken into account as a competing risk. In multivariate logistic regression adjusted for pre-transplant factors including age, gender disparity, disease risk at transplant, prior autologous transplant, GVHD prophylaxis regimens, and stem cell source, presence of any HLA-C mismatch was an independent predictor of grade III-IV acute GVHD (RR 3.6, P ¼ 0.03). However, when patients with combined HLA-C plus other loci mismatch were excluded from the analysis, the association with grade III-IV acute GVHD was no longer statistically significant, and there was only a trend toward increased severe acute GVHD for patients who were mismatched at only HLA-C (P ¼ 0.086).
There was no difference in chronic GVHD incidence between the HLA-C-mismatched and 10/10-matched cohorts, 49 and 54% (P ¼ 0.83), respectively.
Relapse and causes of treatment failure
The 2-year cumulative incidence of treatment failure due to disease relapse was 35% in the HLA-C-mismatched cohort and 55% in the 10/10-matched cohort (P ¼ 0.09). As shown in Figure 2 , the cumulative incidence of transplant-related mortality (TRM) was 48% in the HLA-C-mismatched cohort, compared to only 16% in the 10/10-matched group (P ¼ 0.0001). There was an inverse relationship between TRM and relapse as causes of treatment failure in the two groups. In HLA-C-mismatched patients, 48% experienced treatment failure from TRM, and only 35% from relapse. Conversely, among 10/10-matched patients, a significantly larger proportion (55%) experienced treatment failure from Table 2 Cox regression analysis of pre-transplant factors for overall survival
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Chi Sq P relapse, and only 16% were failing treatment from TRM. At last follow-up, 21 (64%) patients in the HLA-Cmismatched group and 30 (38%) patients in the 10/10-matched group had died. The distribution of causes of death for the two cohorts is shown in Figure 3 . Transplantrelated complications accounted for 14 of 21 (67%) deaths observed in the HLA-C-mismatched patients, and only seven patients had died from disease. Conversely, 19 of the 30 (63%) deaths among patients in the 10/10-matched cohort were caused by disease relapse, and only nine deaths were due to TRM. Taken together, these data demonstrate that the increased mortality observed among HLA-Cmismatched patients was the result of the increased transplant-related complications observed in this cohort.
Discussion
We have described a single institution series of 111 patients receiving URD NST and assessed differences in clinical outcomes with respect to matching at HLA-C. Our results demonstrate that HLA-C mismatch, either alone or in combination with other loci, is associated with inferior overall survival compared to patients who are 10/10 matched at HLA-A, B, C, DRB1 and DQB1. Although there was a baseline difference in the distribution of GVHD prophylaxis regimens between the two cohorts, we believe that this was adjusted for in our multivariate models. These models consistently identified mismatching at HLA-C as the only factor associated with poor OS, independent of GVHD prophylaxis. The reduced survival among HLA-C-mismatched patients is driven by a higher incidence of treatment failure from infection and GVHD. Univariate and multivariate analyses based on the complete cohort of patients with HLA-C mismatch revealed an association for increased grade III-IV acute GVHD. However, in the logistic regression restricted to the subset of patients with HLA-C only mismatch, there was only a trend toward increased grade III-IV acute GVHD (P ¼ 0.086). Therefore, we could not draw any conclusion regarding the impact of isolated HLA-C mismatching on acute GVHD at this time. Further studies, perhaps involving larger populations of patients with isolated HLA-C mismatch, will be necessary to answer this question.
Another observation worth mention is that the deleterious effect of HLA-C mismatching was more pronounced among patients who had received cyclosporine/prednisonebased GVHD prophylaxis, and that the impact of HLA-C on both GVHD and survival could be masked, to some extent, among patients who received a more effective tacrolimus/methotrexate-based GVHD prophylaxis regimen. This result is not surprising, but does have relevant clinical implications as most transplant centers today are employing superior GVHD prophylaxis regimens than cyclosporine/prednisone alone. We acknowledge that among patients receiving better (e.g. tacrolimus and methotrexate) prophylaxis regimens, demonstration of the negative effects from HLA-C disparity would likely require a significantly larger patient population than that included in this study. Nonetheless, we believe that our results are valid because our multivariate models consistently demonstrate HLA-C disparity as a predictor of inferior survival independent of GVHD prophylaxis regimens.
We believe that this study contributes to our understanding of HLA matching and outcome in NST. Niederweiser et al. 4 have reported an unrelated donor transplant series of 52 patients conditioned with fludarabine/low dose TBI, of whom 20 were HLA mismatched. They found a correlation between HLA-class I disparity and grade III-IV acute GVHD (P ¼ 0.06), and there was no discernable impact on engraftment. Maris et al.
1 have reported another series of patients undergoing unrelated donor non-myeloablative transplantation using a fludarabine/low-dose TBI regimen. In their report of 89 patients, 16 had HLA-class I allele mismatches. They observed a trend toward increased risk of graft rejection in the mismatched patients, but no apparent correlation with acute GVHD. In both these studies, no discernable impact on survival for HLA-class I mismatching was reported. The numbers of patients with HLA-class I mismatches in these reports were small, and no detailed information was given regarding any patients with HLA-C disparity.
Our results are also consistent with the literature on myeloablative transplantation where HLA-class I mismatching has been shown to adversely affect clinical outcomes, especially when HLA-C or multiple class I mismatches are involved. 8, 9, 11, [14] [15] [16] [17] In the original report from the Japan Marrow Donor Program, mismatches at HLA-A and HLA-C were associated with increased severe acute GVHD, and the HLA-C-mismatched patients appeared to have a lower incidence of leukemia relapse. 9 Subsequent analysis from the same group extended on this finding, and found a synergistic effect on acute GVHD when HLA-C mismatch was combined with disparity at another HLA-locus. 17 In North American analyses, mismatching at HLA-class I, and in particular, HLA-C, has been associated with a higher risk of graft failure and inferior survival, especially for patients transplanted for chronic myelogenous leukemia in early chronic phase. 8, 12, 16 More recently, the NMDP reported that mismatching at HLA-C exerted significant deleterious effects on acute GVHD and survival comparable in magnitude to mismatching at HLA-A, B, and DRB1. Interestingly, the effect of HLA-C mismatch was most pronounced in HLA-C mismatched detectable by low-resolution typing, which is consistent with our results, as a majority of the HLA-C mismatches in our cohort are detectable at the antigen level.
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In summary, our results suggest that HLA-C disparity could have a significant impact on survival after URD nonmyeloablative transplantation using busulfex and fludarabine conditioning. Further investigation, perhaps through analyses of large transplant registry data, is warranted to confirm the effects of HLA-C mismatching after URD NST. Until those data become available, unrelated donor selection for non-myeloablative transplantation should consider matching at HLA-C wherever possible.
